Successful treatment of hairy cell leukemia variant with rituximab Academic Article uri icon


MeSH Major

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Leukemia, Hairy Cell


  • Hairy cell leukemia (HCL) variant is a rare low-grade B-cell disorder affecting the elderly or middle-aged population with features intermediate between those of HCL and prolymphocytic leukemia. Unlike HCL, it is resistant to most conventional treatment. We report a case of a 53-year-old man who had refractory thrombocytopenia and lymphocytosis for 8 years. Investigations and analysis of spleen and bone marrow revealed a diagnosis of HCL variant. He opted for treatment with rituximab, a chimeric monoclonal antibody targeting CD 20. There was complete recovery of his full blood count and a bone marrow biopsy performed 3 months post-treatment showed complete remission. This is, to our knowledge, the first reported patient with HCL variant for whom treatment with rituximab was successful, and this treatment needs further investigation.

publication date

  • August 2005



  • Academic Article



  • eng

Digital Object Identifier (DOI)

  • 10.1080/10428190500083433

PubMed ID

  • 16085567

Additional Document Info

start page

  • 1229

end page

  • 32


  • 46


  • 8